EP1261314A4 - Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes - Google Patents

Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes

Info

Publication number
EP1261314A4
EP1261314A4 EP01910453A EP01910453A EP1261314A4 EP 1261314 A4 EP1261314 A4 EP 1261314A4 EP 01910453 A EP01910453 A EP 01910453A EP 01910453 A EP01910453 A EP 01910453A EP 1261314 A4 EP1261314 A4 EP 1261314A4
Authority
EP
European Patent Office
Prior art keywords
skin
phytol
composition
present
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01910453A
Other languages
German (de)
English (en)
Other versions
EP1261314A1 (fr
Inventor
Gopinathan K Menon
Dmitri S Ptchelintsev
Harish Mahalingam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/521,442 external-priority patent/US7736661B1/en
Application filed by Avon Products Inc filed Critical Avon Products Inc
Publication of EP1261314A1 publication Critical patent/EP1261314A1/fr
Publication of EP1261314A4 publication Critical patent/EP1261314A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to methods for improving the appearance of skin.
  • the present invention relates to such methods in which topical compositions having phytol in combination with selected ingredients are applied to the skin.
  • compositions containing one or more active ingredients known to beneficially affect the skin Numerous methods have been developed that attempt to improve the appearance of human skin. Many of the more effective methods employ topically applied compositions containing one or more active ingredients known to beneficially affect the skin.
  • compositions containing retinoids include retinol.
  • Retinoids induce and/or promote the biosynthesis and/or bioactivity of endogenous chemicals when topically applied to the skin.
  • retinoids bind to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in the skin.
  • RARs retinoic acid receptors
  • RXRs retinoid X receptors
  • Compositions having retinoid may be used to treat a myriad of unwanted skin conditions, such as acne and wrinkles.
  • consumers with sensitive skin cannot tolerate high levels of retinoids in cosmetic compositions.
  • a composition having phytol is described in JP 10-114648 (1998) to Watanabe et al.
  • the Watanabe application is directed to topical compositions for the prevention and treatment of acne.
  • the effective ingredient of these topical compositions is at least one C 2 o to C 25 terpene alcohol, such as phytol.
  • This citation discloses that therapeutic medicines for common acne can have enhanced effects by using the terpene alcohols with other known anti-acne compounds, such as retinoids.
  • compositions having (i) phytol in an amount about 0.0001 percent by weight (wt%) to about 50 wt% based on the total weight of the composition, and (ii) at least one retinoid in an amount about 0.001 wt% to about 1.5 wt% based on the total weight of the composition.
  • composition used in the method for enhancing the appearance of human skin may have phytol and perilla oil.
  • the present invention is directed to methods of improving the appearance of skin and compositions useful in such methods.
  • Skin conditions that may be treated by methods described herein include dry skin, photodamaged skin, wrinkles, age spots, pigmentary disorders, skin lightening, psoriasis and atopic dermatitis.
  • Some methods according to the present invention may comprise the step of topically applying a composition having phytol and a retinoid.
  • two separate compositions may be contemporaneously applied, in which one composition has phytol and the other composition has a retinoid.
  • Other methods according to the present invention may comprise the step of topically applying a composition having phytol and perilla oil.
  • Phytanic acid is metabolized from phytol when phytol is applied to the skin.
  • Phytanic acid provides independent beneficial skincare effects.
  • phytanic acid also provides a synergistic effect in combination with a retinoid, which provides optimal skincare effects by globally activating retinoic acid receptors (RARs), retinoid X receptors (RXRs), and peroxisome proliferator activated receptor (PPAR) responsive genes.
  • RARs retinoic acid receptors
  • RXRs retinoid X receptors
  • PPAR peroxisome proliferator activated receptor
  • phytanic acid activates or "upregulates" PPAR responsive genes.
  • Upregulation of PPAR responsive genes has been documented to improve the skin barrier function and, hence, moisture retention by skin.
  • compositions containing phytanic acid precursors such as phytol.
  • adverse or deleterious effects of retinoids such as dry skin, flaky skin and/or reddened skin (i.e. sensitized), are minimized by retention of moisture in the skin due to PPAR receptor upregulation.
  • phytanic acid is a recognized RXR agonist competing with retinoids, such retinol, at the receptor site.
  • retinoids such retinol
  • phytanic acid will bind and activate available RXR sites, leaving only RAR sites available for binding and activating with a lesser or smaller level of retinoids.
  • combining phytanic acid with one or more retinoids enhances the efficacy of the retinoids by increasing the number of RAR sites activated absent the presence of phytanic acid.
  • methods according to the present invention provide multiple skin care benefits by simultaneously and/or contemporaneously activating RXRs, PPARs, and, preferably, RARs.
  • Activating these receptors and responsive genes stimulates cell functions in multiple components of skin, such as the epidermis, dermis, sebaceous glands, melanocytes, Langerhan cells, and hair follicles.
  • R is selected from a group of substituents that includes hydrogen, as well as cyclic and acyclic hydrocarbon residues, which may contain one or several unsaturated bonds and/or heteroatomic substituents.
  • the preferred substituents are hydrogen, acyls and cyclic or linear alkyls.
  • phytol encompasses phytol, phytol derivatives, phytol precursors, and phytol metabolites, preferably phytanic acid.
  • Metabolic precursors of phytol are hereby defined as compounds from which phytol can be formed by action of enzymes present in human tissues, particularly skin.
  • retinoid includes: (1 ) retinol; (2) esters of retinol with carboxylic acids of 1 to 24 carbon atoms, such as retinyl acetate, retinyl propionate, retinyl butyrate, retinyl octanoate, retinyl laurate, retinyl palmitate, retinyl oleate, retinyl linoleate; (3) esters of retinol having an alpha-hydroxy carboxylic acid; (4) ether derivatives of retinol, including alkyl ether, ethers derived from glycolic acid, as well as glycolate ester and amide, such as retinyl glycolyl ether; (5) retinaldehyde; (6) retinoic acid; (7) esters of retinoic acid with alcohols of 1 to 24 carbon atoms; (8) isotretinoin as well as synthetic retinoid mimics, and
  • compositions that can be used in the methods of the present invention will have phytol in an amount about 0.0001 percent by weight (wt%) to about 50 wt% based on the total weight of the composition.
  • phytol may be present in an amount about 0.01 wt% to about 20 wt%, and most preferably about 0.1 wt% to about 15 wt%, based on the total weight of the composition.
  • phytol synergistically enhances the effect of the retinoid which is preferably present in the composition.
  • compositions used in the methods of the first embodiment of the present invention may have a retinoid in an amount about 0.001 wt% to about 1.5 wt% based on the total weight of the composition.
  • the retinoid is present in an amount about 0.01 wt% to about 1 wt%, and most preferably about 0.1 wt% to about 0.5 wt%, based on the total weight of the composition.
  • the amount of retinoid may be adjusted, based upon the potency of the retinoid, without departing from the present invention.
  • the synergistic effect is achieved within the broadest range set forth above for the phytol and the retinoid, but will vary within the ranges depending on many factors including the potency of the retinoid.
  • methods according to the present invention comprise the step of topically applying one or more compositions to the skin for improving the appearance of the skin.
  • methods according to the present invention comprise the step of topically applying a composition as described herein at least once daily for a period of time, namely at least two days, to effect the desired improvement.
  • methods according to the present invention may involve topically applying a single composition that has phytol and a retinoid.
  • An alternative to the first embodiment is that two separate compositions may be contemporaneously applied, each of which has only one of either the phytol or the retinoid.
  • the second embodiment of the methods according to the present invention comprise the step of topically applying a composition having phytol and perilla oil. For both embodiments, additional ingredients may be added as discussed below.
  • the improvement in the appearance of skin may be demonstrated by reducing dermatological aging, particularly dermatological aging due to intrinsic aging, such as chronological aging resulting from peri-menopausal or post menopausal changes, and extrinsic aging, such as photo-aging and effects of pollution; decreasing skin fragility; preventing and reversing loss of collagen and/or elastin; preventing skin atrophy; promoting/accelerating cell turnover; improving skin firmness/plumpness; improving skin texture; preventing and decreasing fine lines and wrinkles; improving skin tone; enhancing skin thickness; decreasing pore size; minimizing skin discoloration; restoring skin luster; minimizing signs of fatigue; improving skin barrier function; minimizing skin dryness; and preventing, reducing, or treating hyperpigmentation, especially associated with blemishes.
  • the second embodiment of the present invention provides methods in which the composition includes phytol, in the amounts set forth in the first embodiment, and perilla oil.
  • the perilla oil is present in an amount about 0.01 wt% to about 10 wt%. Preferably, the perilla oil is present in an amount about 1 wt% to about 8 wt%, and most preferably about 3 wt% to about 6 wt%.
  • Perilla oil is the subject of pending U.S. application Ser.No. 09/521 ,442, filed March 7, 2000, noted above, which application is incorporated herein by reference.
  • the compositions of the second embodiment are used in methods for improving the appearance of the human skin. In addition, these compositions of the second embodiment can also be used to prevent, reduce and/or treat acne.
  • compositions useful in either embodiment of the methods of the present invention may have an acceptable topical vehicle.
  • the vehicle must be adapted to receive, for the first embodiment, the phytol and, preferably, also the retinoid.
  • the vehicle must be adapted to receive the phytol and the perilla oil.
  • an acceptable vehicle examples include a lotion, a cream, a gel, a spray, an ointment, a serum, a patch, a foundation, a stick, and/or another form known to those skilled in the art.
  • compositions useful in the methods of the first and second embodiments of the present invention may, and preferably do, include an anti-inflammatory agent.
  • Suitable anti-inflammatory agents include, but are not limited to, salicylic acid, boswellic acid, curcumin, tetrahydrocurcumin, ferulic acid and its derivatives, rosmarinic acid, catechins, and bisabolol.
  • the anti-inflammatory agent is salicylic acid.
  • compositions useful in the methods of the first and second embodiments of the present invention may, and preferably do, include a 5- alpha reductase inhibitor.
  • Suitable inhibitors include, but are not limited to, saw palmetto and finasteride.
  • compositions useful in the methods of the first and second embodiments of the present invention may include one or more exfoliants.
  • Suitable exfoliants include, but are not limited to, alpha-hydroxy acid, beta-hydroxy acid, keto acid, niacinamide, oxa acid or oxa diacid (disclosed in U.S. Patent Nos. 5,847,003 and 5,834,513), and combinations thereof.
  • Preferred alpha-hydroxy acids include lactic acid, glycolic acid or a mixture thereof.
  • the preferred oxa diacid is 3,6,9-trioxaundecanedioic acid.
  • the exfoliant is or includes niacinamide.
  • compositions useful in the methods of the first and second embodiments of the present invention may also include one or more hypopigmenting agents.
  • the hypopigmenting agent includes, but is not limited to, hydroquinone ascorbic acid and/or licorice extract; and ascorbyl- phosporyl-cholesterol that is disclosed in U.S. Patent No. 5,866,147.
  • compositions useful in the methods of the first and second embodiments of the present invention may include one or more sunscreens.
  • sunscreens include, but are not limited to, oxybenzone, octyl salicylate, octyl methoxycinnamate, octocrylene, titanium dioxide, zinc oxide, butylmethoxydibenzoylmethane, methylene bis- benzotriazoyl tetramethylbutylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT), or any combinations thereof.
  • MBT methylene bis- benzotriazoyl tetramethylbutylphenol
  • BEMT bis-ethylhexyl oxyphenol methoxyphenol triazine
  • antioxidants may be included in the compositions used in the methods of the first and second embodiments of the present invention.
  • Suitable antioxidants include, but are not limited to, compounds having phenolic hydroxy functions, such as ascorbic acid and ascorbic acid derivatives; gallic acid and its derivatives (e.g. propyl gallate); ferulic acid and its derivatives (e.g.
  • ethyl ferulate sodium ferulate
  • nitrones N- tertbutyl-nitrone
  • curcumin tetrahydrocurcumin
  • 6-hydroxy-2,5,7,tetramethylchroman-2-carboxylic acid uric acid
  • reductic acid tannic acid
  • rosmarinic acid tocopherol and its derivatives
  • catechins and mixtures thereof.
  • antioxidants are those that have one or more thiol functionals (-SH), in either reduced or non-reduced form, such as glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds.
  • the antioxidant may be inorganic, such as a sulfite, bisulfite, metabisulfite, or another inorganic salt and/or acid containing sulfur.
  • the antioxidant is or includes tetrahydrocurcumin.
  • Compositions useful in the methods of the first and second embodiments of the present invention may include one or more barrier function enhancing agents.
  • Examples include ceramides; essential fatty acids and their esters, especially glycerides, ⁇ -hydroxy fatty acids and their esters, ⁇ -hydroxy fatty acids and their esters; phospholipids; cholesterol and its esters, such as cholesteryl hemisuccinate, cholesteryl phosphate; and cholestanol and its derivatives.
  • the barrier function enhancing agent can be added to a topical composition either as singular molecular entities or as a complex mixture of lipids derived from either synthetic, animal or plant sources.
  • compositions useful in the methods of the first and second embodiments of the present invention may include one or more collagen enhancing agents. These agents prevent skin sagging by promoting a net increase in collagen, either by reducing collagen breakdown or by promoting collagen formation.
  • collagen enhancing agents include Clara extract (Sophora augustifolia), ascorbyl-phoshoryl- cholesterol, ascorbic acid, ascorbic acid derivatives, and mixtures thereof.
  • compositions useful in the methods of the first and second embodiments of the present invention may include one or more elastase inhibitors.
  • these inhibitors include fatty acids, such as oleic acid, perinaric acid, and Honeysuckle extract ⁇ Lonicera caprifolium). These inhibitors act to prevent sagging of the skin.
  • compositions useful in the methods of the first and second embodiments of the present invention may include one or more phytoestrogens.
  • Phytoestrogens are described in PCT WO 00/13661 , which is incorporated herein by reference.
  • Compositions useful in the methods of the first and second embodiments of the present invention may include additional ingredients.
  • additional ingredients may be one or more bulking agents, clays, emollients, emulsifiers, fillers, fragrances, gellants, germicides, humectants, lipid materials, moisturizers, natural oils, perfumes, polymers, preservatives, solvents, stabilizers, thickeners, ultraviolet light absorbers, skin cooling agents, skin protectants, penetration enhancers, vitamins, waxes, or any combinations thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes d'amélioration de l'apparence de la peau humaine, lesdites méthodes consistant à appliquer une composition renfermant (i) du phytol dans une quantité comprise entre environ 0,0001 et 50 % en poids en fonction du poids total de la composition et (ii) au moins un rétinoïde dans une quantité comprise entre environ 0,001 et 1,5 % en poids du poids total de la composition. Dans un autre mode de réalisation, la composition utilisée dans la méthode d'amélioration de l'apparence de la peau humaine peut renfermer du phytol et de l'huile de périlla.
EP01910453A 2000-03-07 2001-02-08 Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes Withdrawn EP1261314A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US09/521,442 US7736661B1 (en) 2000-03-07 2000-03-07 Method of treating skin conditions
US521442 2000-03-07
US19098900P 2000-03-21 2000-03-21
US19098800P 2000-03-21 2000-03-21
US190989P 2000-03-21
US190988P 2000-03-21
US72435600A 2000-11-28 2000-11-28
US724356 2000-11-28
PCT/US2001/003965 WO2001066080A1 (fr) 2000-03-07 2001-02-08 Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes

Publications (2)

Publication Number Publication Date
EP1261314A1 EP1261314A1 (fr) 2002-12-04
EP1261314A4 true EP1261314A4 (fr) 2003-06-11

Family

ID=27497872

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01910453A Withdrawn EP1261314A4 (fr) 2000-03-07 2001-02-08 Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes

Country Status (2)

Country Link
EP (1) EP1261314A4 (fr)
WO (1) WO2001066080A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179286A (ja) * 2003-12-22 2005-07-07 Nikko Chemical Co Ltd ヒアルロン合成促進剤の皮膚老化防止剤への利用
US9757327B2 (en) * 2013-03-14 2017-09-12 Avon Products, Inc. Abutilon indicum extracts and methods of use
BR112017019054B1 (pt) 2015-03-05 2021-05-11 Avon Products, Inc método cosmético, não terapêutico, para diminuir sinais dermatológicos de envelhecimento em pele humana e produtos para cuidados com a pele
US10076479B1 (en) 2018-05-08 2018-09-18 Avon Products, Inc. Methods for treating skin
CN110215421A (zh) * 2019-05-21 2019-09-10 广州市拉凯尔干细胞研究所 一种促进角质细胞核内健康基因表达的护肤品制备方法
CN115381803B (zh) * 2022-09-30 2023-09-15 深圳浦瑞健康科技有限公司 类视黄醇组合物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014093A1 (fr) * 1989-05-22 1990-11-29 Iowa State University Research Foundation, Inc. Preparations de vitamine a solubles dans l'eau s'appliquant sur la peau
WO1993019743A1 (fr) * 1992-03-31 1993-10-14 The Regents Of The University Of Michigan PROCEDE DE TRAITEMENT DE L'HYPERPIGMENTATION DE LA PEAU CHEZ LES NOIRS AU MOYEN DE l'ACIDE RETINOIQUE ET PROCEDE D'ECLAIRCISSEMENT DE LA PEAU CHEZ LES NOIRS PAR DE L'ACIDE RETINOIQUE
WO1995003772A1 (fr) * 1993-07-30 1995-02-09 Unilever Plc Microemulsions cosmetiques hydro-acooliques
WO1997009039A2 (fr) * 1995-09-08 1997-03-13 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Composition contenant de la vitamine f
US5670547A (en) * 1989-04-17 1997-09-23 Dow Pharmaceutical Sciences Moisturizing vehicle for topical application of vitamin A acid
US5719195A (en) * 1995-05-05 1998-02-17 4 Thought Technologies Treatment of psoriasis with 11-cis-retinoic acid
WO1998036742A1 (fr) * 1997-02-25 1998-08-27 The Regents Of The University Of Michigan Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age
DE10038641A1 (de) * 2000-07-28 2002-02-14 Heinz Nau Pharmazeutische Zusammensetzungen mit Retinol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421185D0 (en) * 1994-10-20 1994-12-07 Unilever Plc Personal car composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670547A (en) * 1989-04-17 1997-09-23 Dow Pharmaceutical Sciences Moisturizing vehicle for topical application of vitamin A acid
WO1990014093A1 (fr) * 1989-05-22 1990-11-29 Iowa State University Research Foundation, Inc. Preparations de vitamine a solubles dans l'eau s'appliquant sur la peau
WO1993019743A1 (fr) * 1992-03-31 1993-10-14 The Regents Of The University Of Michigan PROCEDE DE TRAITEMENT DE L'HYPERPIGMENTATION DE LA PEAU CHEZ LES NOIRS AU MOYEN DE l'ACIDE RETINOIQUE ET PROCEDE D'ECLAIRCISSEMENT DE LA PEAU CHEZ LES NOIRS PAR DE L'ACIDE RETINOIQUE
WO1995003772A1 (fr) * 1993-07-30 1995-02-09 Unilever Plc Microemulsions cosmetiques hydro-acooliques
US5719195A (en) * 1995-05-05 1998-02-17 4 Thought Technologies Treatment of psoriasis with 11-cis-retinoic acid
WO1997009039A2 (fr) * 1995-09-08 1997-03-13 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Composition contenant de la vitamine f
WO1998036742A1 (fr) * 1997-02-25 1998-08-27 The Regents Of The University Of Michigan Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age
DE10038641A1 (de) * 2000-07-28 2002-02-14 Heinz Nau Pharmazeutische Zusammensetzungen mit Retinol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAPOLI J L: "Interactions of retinoid binding proteins and enzymes in retinoid metabolism", BIOCHEMICA AND BIOPHYSICA ACTA, vol. 1440, no. 2-3, 22 September 1999 (1999-09-22), nl, pages 139 - 162, XP004277240 *
See also references of WO0166080A1 *
SUTISAK KITAREEWAN ET AL: "PHYTOL METABOLITES ARE CIRCULATING DIETARY FACTORS THAT ACTIVATE THE NUCLEAR RECEPTOR RXR", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, vol. 7, no. 8, 1 August 1996 (1996-08-01), pages 1153 - 1166, XP000611599, ISSN: 1059-1524 *

Also Published As

Publication number Publication date
EP1261314A1 (fr) 2002-12-04
WO2001066080A1 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
JP4256389B2 (ja) テトラペプチドとトリペプチドの混合物を含む組成物
US6333356B1 (en) Compounds for treating skin conditions
US5834513A (en) Oxa diacids and related compounds for treating skin conditions
KR100455470B1 (ko) 피토스테롤 조성물의 국소 적용을 통한 포유류 케라틴조직 상태의 조절 방법
JP4234137B2 (ja) ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整
US5932229A (en) Oxa diacids and related compounds for treating skin conditions
US20140206842A1 (en) Peptides Modified with Triterpenoids and Small Organic Molecules: Synthesis and use in Cosmeceutical
JP2006524187A (ja) 哺乳類のケラチン組織の外観を改善する手段
MXPA04009370A (es) Metodos para regular la condicion del tejido queratinoso de mamiferos por medios de la aplicacion topica de composiciones de vitamina b6.
MXPA01010630A (es) Composiciones para el cuidado de la piel que contienen una combinacion de ingredientes activos para el cuidado de la piel.
JP2009137984A (ja) 天然成分を含有する局所用組成物及び使用方法
US5922335A (en) Uses for ascorbyl-phosphoryl-cholesterol in topical compositions
WO2000013661A1 (fr) Procede et compositions pour reduire le vieillissement de la peau et les contusions
US8383594B2 (en) Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceuticals
US7736661B1 (en) Method of treating skin conditions
US20030198657A1 (en) Methods using phytol to improve the appearance of skin and compositions for such methods
US20040131579A1 (en) Method and compositions for reducing dermatological aging and for reducing bruising
EP1261314A1 (fr) Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes
US20050136015A1 (en) Topical use of halosalicylic acid derivatives
WO2023212003A1 (fr) Compositions topiques contenant de la vitamine c
MXPA00004471A (en) Method and compositions for reducing dermatologicalaging and for reducing bruising
KR20050089045A (ko) 수용성 비타민 ｅ에 의한 피부 세포 재생의 증가
JPH10212231A (ja) 皮膚の状態を手入れするためのオキサ・ジアシッドと関連化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020924

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAHALINGAM, HARISH

Inventor name: MENON, GOPINATHAN, K.

Inventor name: PTCHELINTSEV, DMITRI, S.

A4 Supplementary search report drawn up and despatched

Effective date: 20030429

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/01 A

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAHALINGAM, HARISH

Inventor name: PTCHELINTSEV, DMITRI, S.

Inventor name: MENON, GOPINATHAN, K.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080211